Invega Trinza Injection, Suspension, Extended Release
Pricing Report NDC 50458-609-01

Current Package Pricing Information

The current wholesale acquisition cost for Invega Trinza (NDC 50458-609-01) is $4001.52592 per ML. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Jun 17, 2026.

As a a human prescription drug provided by Janssen Pharmaceuticals, Inc, this medication is distributed in a 1 SYRINGE in 1 KIT / 1 mL in 1 SYRINGE configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.

Historical Pricing Trends & Acquisition Cost Benchmarks

Since Jan 2016, the NADAC wholesale price for (NDC ) has moved within a range of $2,336.61173 to $4,007.78113 per ML. Over this 10 years and 4 months period, the pricing trend reflects the shifting acquisition costs reported by retail and chain pharmacies to the Centers for Medicare and Medicaid Services (CMS). The following interactive chart and historical table detail every recorded price adjustment based on these federal surveys.

Understanding NADAC Pricing Data

The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.

Important Price Distinction:

The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.

NADAC Pricing Data Last Updated on: July 08, 2026